Lisdexamfetamine Dimesylate | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Lisdexamfetamine Dimesylate
Health Canada Patents

PharmaCompass Sponsored Ads

Contact Supplier

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Lisdexamfetamine Dimesylate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

22 API Suppliers, 10 USDMF, 2 EU WC, 11 NDC API, 14 Listed Suppliers, $ API Reference Price

22 API Suppliers
10 USDMF
2 EU WC
11 NDC API
14 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

267 FDF Dossiers, 160 FDA Orange Book, 58 Europe, 33 Canada, 6 Australia, 3 South Africa, 7 Listed Dossiers

267 FDF Dossiers
160 FDA Orange Book
58 Europe
33 Canada
6 Australia
3 South Africa
7 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 10MG, CAPSULE;ORAL - 20MG, CAPSULE;ORAL - 30MG, CAPSULE;ORAL - 40MG, CAPSULE;ORAL - 50MG, CAPSULE;ORAL - 60MG, CAPSULE;ORAL - 70MG

CAPSULE;ORAL - 10MG
CAPSULE;ORAL - 20MG
CAPSULE;ORAL - 30MG
CAPSULE;ORAL - 40MG
CAPSULE;ORAL - 50MG
CAPSULE;ORAL - 60MG
CAPSULE;ORAL - 70MG

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 14 SPI Pharma, 8 DKSH, 1 Pharm-RX Chemical, 4 Faran Shimi Pharmaceutical, 5 Gangwal Healthcare, 1 Pfanstiehl, 4 ACG Worldwide, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 1 Bioplus Life Sciences, 3 DFE Pharma, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 5 Kerry, 3 Lonza Capsugel, 9 Microlex e.U, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 1 Qualicaps, 13 Roquette, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 3 Vasa Pharmachem

2 Rochem International Inc
14 SPI Pharma
8 DKSH
1 Pharm-RX Chemical
4 Faran Shimi Pharmaceutical
5 Gangwal Healthcare
1 Pfanstiehl
4 ACG Worldwide
5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
1 BASF
1 Bioplus Life Sciences
3 DFE Pharma
5 Gangwal Chemicals
1 Ideal Cures Pvt Ltd
2 Ingredion Pharma Solutions
5 Kerry
3 Lonza Capsugel
9 Microlex e.U
1 Pharmatrans-Sanaq
4 Pluviaendo
3 Prachin Chemical
1 Qualicaps
13 Roquette
4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Shijiazhuang Huaxu Pharmaceutical
9 Sigachi Industries
3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

39 Fillers, Diluents & Binders, 18 Direct Compression, 17 Disintegrants & Superdisintegrants, 15 Thickeners and Stabilizers, 14 Taste Masking, 12 Chewable & Orodispersible Aids, 10 Lubricants & Glidants, 10 Co-Processed Excipients, 10 Granulation, 8 Empty Capsules, 7 Coating Systems & Additives, 4 Parenteral, 3 Coloring Agents, 3 Controlled & Modified Release, 3 Emulsifying Agents, 3 Film Formers & Plasticizers, 2 Rheology Modifiers, 1 API Stability Enhancers, 1 Solubilizers

39 Fillers, Diluents & Binders
18 Direct Compression
17 Disintegrants & Superdisintegrants
15 Thickeners and Stabilizers
14 Taste Masking
12 Chewable & Orodispersible Aids
10 Lubricants & Glidants
10 Co-Processed Excipients
10 Granulation
8 Empty Capsules
7 Coating Systems & Additives
4 Parenteral
3 Coloring Agents
3 Controlled & Modified Release
3 Emulsifying Agents
3 Film Formers & Plasticizers
2 Rheology Modifiers
1 API Stability Enhancers
1 Solubilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 42 News #PharmaBuzz

1 Data Compilation #PharmaFlow
42 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 55 Regulatory FDF Prices, 10 Annual Reports

1 US Medicaid Prescriptions
55 Regulatory FDF Prices
10 Annual Reports

MARKET PLACE

12 APIs, 3 FDF Dossiers

12 APIs
3 FDF Dossiers

PATENTS & EXCLUSIVITIES

7 Health Canada Patents

7 Health Canada Patents

$ API Ref.Price (USD/KG) : 4,050 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

7 All

01 7Gowling WLG (Canada) LLP

filter Patent Reset all filters

7 All

01 72527646

filter Product Reset all filters

7 All

01 2LISDEXAMFETAMINE DIMESYLATE

02 5Lisdexamfetamine Dimesylate

filter Dosage Reset all filters

7 All

01 2CAPSULE

02 5Capsule

filter Exp Date Reset all filters

7 All

01 72024-06-01

Lisdexamfetamine Dimesylate

Product Main Page

01

Gowling WLG (Canada) LLP

Lisdexamfetamine Dimesylate

OPRD USA

Not Confirmed

Gowling WLG (Canada) LLP

Canada

OPRD USA

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Lisdexamfetamine Dimesylate

Brand Name : VYVANSE

Patent Number : 2527646

Filing Date : 2004-06-01

Strength per Unit : 60 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling WLG (Canada) LLP

Lisdexamfetamine Dimesylate

OPRD USA

Not Confirmed

Gowling WLG (Canada) LLP

Canada

OPRD USA

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Lisdexamfetamine Dimesylate

Brand Name : VYVANSE

Patent Number : 2527646

Filing Date : 2004-06-01

Strength per Unit : 30 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Gowling WLG (Canada) LLP

Lisdexamfetamine Dimesylate

OPRD USA

Not Confirmed

Gowling WLG (Canada) LLP

Canada

OPRD USA

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Lisdexamfetamine Dimesylate

Brand Name : VYVANSE

Patent Number : 2527646

Filing Date : 2004-06-01

Strength per Unit : 50 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Gowling WLG (Canada) LLP

Lisdexamfetamine Dimesylate

OPRD USA

Not Confirmed

Gowling WLG (Canada) LLP

Canada

OPRD USA

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Lisdexamfetamine Dimesylate

Brand Name : VYVANSE

Patent Number : 2527646

Filing Date : 2004-06-01

Strength per Unit : 20 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Gowling WLG (Canada) LLP

Lisdexamfetamine Dimesylate

OPRD USA

Not Confirmed

Gowling WLG (Canada) LLP

Canada

OPRD USA

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Lisdexamfetamine Dimesylate

Brand Name : VYVANSE

Patent Number : 2527646

Filing Date : 2004-06-01

Strength per Unit : 40 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Gowling WLG (Canada) LLP

Lisdexamfetamine Dimesylate

OPRD USA

Not Confirmed

Gowling WLG (Canada) LLP

Canada

OPRD USA

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Lisdexamfetamine Dimesylate

Brand Name : VYVANSE

Patent Number : 2527646

Filing Date : 2004-06-01

Strength per Unit : 10mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Gowling WLG (Canada) LLP

Lisdexamfetamine Dimesylate

OPRD USA

Not Confirmed

Gowling WLG (Canada) LLP

Canada

OPRD USA

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Lisdexamfetamine Dimesylate

Brand Name : VYVANSE

Patent Number : 2527646

Filing Date : 2004-06-01

Strength per Unit : 70 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2024-06-01

Date Granted : 2011-08-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!